Japan — Fishery/Seafood Products — Squid-Octopus

← back to leaderboard

Japan received 2 FDA import refusals in Squid-Octopus, part of Fishery/Seafood Products between 2021-Q4 and 2024-Q3. Volume is newly active in the last year. The most-cited issues are listeria, added bulk, and mfrhaccp. No trade baseline is published for this commodity from Japan, so no per-$1B rate is shown here.

Of these, 2 were hazard refusals and 0 were paperwork refusals.

Exporting from Japan? Get an email when shipments from Japan are refused at the US border — before your buyers ask.

Quarterly rejections, last 12 quarters

0 2021-Q4 2021-Q4: 0 0 2022-Q1 2022-Q1: 0 0 2022-Q2 2022-Q2: 0 0 2022-Q3 2022-Q3: 0 0 2022-Q4 2022-Q4: 0 0 2023-Q1 2023-Q1: 0 0 2023-Q2 2023-Q2: 0 0 2023-Q3 2023-Q3: 0 0 2023-Q4 2023-Q4: 0 0 2024-Q1 2024-Q1: 0 0 2024-Q2 2024-Q2: 0 2 2024-Q3 2024-Q3: 2

Recent rejections